Zobrazeno 1 - 3
of 3
pro vyhledávání: '"May Klink-Alakl"'
Autor:
Michael Murawsky, Marcus Hudec, M. Baur, Christian Dittrich, May Klink-Alakl, Michèle Tubiana-Hulin, Allan T. van Oosterom, Véronique Diéras, R. Charles Coombes, Thomas Hatschek
Publikováno v:
Journal of cancer research and clinical oncology. 134(2)
The efficacy and tolerability of docetaxel 100 mg/m(2) every 3 weeks as second-line chemotherapy in patients with metastatic breast cancer was investigated. In addition, the efficacy of a 3-day prophylaxis against cumulative dose-related fluid retent
Autor:
May Klink-Alakl, Guy G. Chabot, D Abigerges, Martine Bayssas, Jean-Pierre Armand, G. Catimel, Marie-Christine Bissery, M. Clavel, Ren Bruno
Publikováno v:
Anti-cancer drugs. 7(2)
Intoplicine (RP 60475F; NSC 645008) is a novel 7H-benzo[e]pyrido[4,3-b]indole derivative which interacts with both topoisomerases I and II. Because of its high activity in preclinical cancer models, original mechanism of action and acceptable toxicit
Autor:
Daniel D. Von Hoff, John R. Eckardt, John G. Kuhn, Marie Christine Bissery, Gary M. Clark, Howard A. Burris, May Klink-Alakl
Publikováno v:
Journal of the National Cancer Institute. 86(1)
Background Intoplicine (RP60475) is the most active analogue evaluated in the 7H-benzo[e]-pyrido-[4,3-b]-indole series of antineoplastic compounds. It exerts its activity through inhibition of DNA topoisomerase I and II. Purpose This study was planne